Pharma contracts take 12–18 months. Mitigation: Start with Apollo + academic anchor customers (3–6 month cycles). Use DBT/BIRAC grants for non-dilutive bridge. Recurring PV contracts and LabOS SaaS subscriptions build base revenue in parallel.
Computational biologists + ML engineers are scarce in India. Mitigation: Partner with IISc, IITB, IITH, NCBS for PhD pipelines. Equity-heavy senior offers. Remote-first to access India diaspora (US/UK returnees). Apollo gives access to clinician collaborators.
DPDP Act 2023 + ICMR genomic data guidelines + Apollo's own data governance. Mitigation: Federated learning where raw data never leaves Apollo. Consent-tracking layer. Differential privacy on Atlas outputs. Sovereign-cloud fine-tuned model (USP 5) eliminates frontier-API data exposure.
Wet lab partners may not meet quality standards. Mitigation: Multi-CRO redundancy via Execution Broker. LabOS QC Agent enforces quality gates on every node. SLA-backed contracts with capability-registry-published specs. FAL Pods in Phase 2 as fallback.
Ginkgo or Recursion could open an India POP. Mitigation: Apollo exclusivity clauses. India Biomarker Atlas is a 3–5 year lead. Regulatory relationships + DPDP-compliant deployment cannot be replicated overnight. The experimental graph + LIMS lock-in is the long-term moat.
AI predictions may not validate in wet lab. Mitigation: Systematic uncertainty quantification built into Hypothesis Agent. Internal red-team and held-out eval harness. Published validation benchmarks. Customer co-development shares risk.
Single-point-of-failure on the data substrate. Mitigation: Negotiate 5–7 year exclusivity but with non-cancellable data rights to records generated during the term. Parallel MoUs in Year 2 with Fortis, AIIMS, CMC as secondary substrates. Make Apollo's economic stake high enough that exit is irrational.
Anthropic / OpenAI pricing changes or policy shifts. Mitigation: Multi-model abstraction layer from day 1; every prompt/response captured as distillation data; Year-2 sovereign-cloud fine-tuned model serves 80%+ of agent calls.
The agent mesh introduces a class of risks that do not exist in conventional SaaS. Each is paired with a concrete control built into LabOS, not bolted on. These controls are themselves a sellable feature — pharma QA buyers ask about them on day one.
| Failure mode | Concrete consequence | Mitigation built into LabOS |
|---|---|---|
| Agent designs an incorrect protocol | $10K–100K of wasted reagents + 2–6 weeks lost cycle time | Mandatory human-in-the-loop sign-off at the Design→Execution boundary. Design Agent surfaces budget impact, scientific risk score, and uncertainty before submission. Scientist signature captured as preference data feeding the Learning Agent. |
| Hypothesis Agent hallucinates a target or mechanism | Wasted Discovery Sprint, customer trust damage | Grounded retrieval — every claim must cite an Atlas record or peer-reviewed paper. Uncertainty quantification on every ranked hypothesis. Confidence threshold below which the agent refuses to commit; escalates to human. |
| Cross-agent context drift | Design Agent misinterprets Hypothesis Agent's intent; protocol diverges from goal | Typed contracts between agents (Protocol IR schemas). Schema validation on every handoff. Replay tests on held-out trajectories before any agent version is promoted to production. |
| Stale or wrong instrument state | Agent submits run to a machine that's down, drift-flagged, or out of reagents | Real-time capability registry with liveness checks (heartbeat from each instrument/CRO). Circuit breakers per node. Execution Broker dynamically re-routes; if no path exists, queues and notifies. |
| Training-data bias (Western-skewed models) | Hypotheses miss India-specific biology (e.g., HLA-B*57:01 PGx, NAFLD phenotypes) | India-cohort fine-tuning pipeline (USP 5). Per-vertical bias audits. Held-out India-population eval set. Refuse-to-commit if predictions diverge significantly from Apollo cohort priors. |
| Regulatory non-compliance from autonomous workflow | CDSCO / FDA / NABL audit failure; data inadmissible | Provenance signing (Ed25519) on every datapoint. GxP-compliant audit trail by construction. Risk-based qualification matrix — every operation tagged "human-required" / "agent-OK" / "agent-with-checkpoint". CDSCO pre-consultation in Year 1. |
| Patient data leakage via agent prompts | DPDP Act violation, Apollo MoU breach, criminal liability | Patient data never enters frontier-API prompts. On-prem retrieval at Apollo; only de-identified embeddings or aggregates traverse the agent mesh. Year-2 sovereign-cloud model eliminates exposure entirely. DLP scanning on every outbound API call. |
| Agent does something irreversible (sample destroyed, sequencing run committed) | Lost biospecimen — irreplaceable; sunk cost on sequencing | Two-key authorization for any irreversible operation. Cost-and-irreversibility classifier on every action. Dry-run / simulation mode by default; "commit" is a separate explicit step. Sample-criticality registry (Apollo biobank items flagged). |
| Adversarial inputs / prompt injection from external data | Agent manipulated by malicious paper, fake reagent record, compromised CRO API | Treat all external inputs as untrusted. Quarantine + provenance check on ingest. Capability sandboxing — agents can only act through the capability registry, not arbitrary tools. Red-team eval suite run weekly. |
| Cascading failure across the mesh | One bad agent decision propagates; many programs corrupted simultaneously | Per-program isolation; no shared mutable state across customer tenants. Canary deployment for agent model updates. Rollback to any prior graph state (content-addressed store enables time-travel debugging). |
Most agentic-AI products treat these controls as compliance overhead. We treat them as product. The provenance graph, the human-in-the-loop checkpoint, the dry-run mode, the capability sandbox — these are the answers to every pharma QA, regulator, and CISO question, packaged as the platform's day-one UX. "The scientist signs every plan; we make signing easy."